On April 16, 2024, Asher Biotherapeutics, Inc. closed the transaction. The company received $55,000,000 in a round of funding led by returning investor, RA Capital Management, L.P. The transaction included participation from new investors, AstraZeneca PLC, Bristol-Myers Squibb Company, returning investors Janus Henderson Investors US LLC, Third Rock Ventures, LLC, Wellington Management Company LLP, Boxer Capital LLC and other undisclosed institutional investors. The transaction included participation from 16 investors pursuant to regulation D.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,156 GBX | -0.12% | +7.88% | +14.68% |
05:18pm | AstraZeneca Says Calquence Combination Improves Progression-Free Survival in Phase 3 Mantle Cell Lymphoma Trial | MT |
04:46pm | AstraZeneca: research into respiratory diseases | CF |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
12,156 GBX | -0.12% | +7.88% | 236B | ||
43.7 USD | -1.15% | -2.24% | 89.62B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.68% | 236B | |
+29.68% | 699B | |
+25.07% | 571B | |
-4.35% | 364B | |
+17.65% | 326B | |
+3.77% | 286B | |
+4.71% | 198B | |
-12.43% | 194B | |
-3.79% | 154B | |
-3.34% | 149B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- Asher Biotherapeutics, Inc. announced that it has received $55 million in funding from a group of investors